- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Sunscreen regulations take effect
Washington - The Food and Drug Administration’s final rule for sunscreen labeling requirements went into effect Dec. 17, impacting manufacturers with annual product sales of more than $25,000.
Sunscreen regulations take effect
Jan 4, 2013
By: Sarah Thuerk
Dermatology Times E-News
Washington - The Food and Drug Administration’s final rule for sunscreen labeling requirements went into effect Dec. 17, impacting manufacturers with annual product sales of more than $25,000.
The FDA’s final rule calls for some manufacturers of over-the-counter sunscreens to pass new broad-spectrum tests. Broad-spectrum sunscreens with sun protection factor (SPF) values of 15 or higher can make claims related to skin cancer protection and early skin aging. Those products that are not broad-spectrum must include a warning that the product will only protect against sunburn, not skin cancer or photoaging.
Manufacturers producing sunscreen products with annual sales of less than $25,000 have until Dec. 17, 2013 to comply to the final rule, according to the FDA. After that date, any sunscreen manufacturers whose products have annual sales of more than $25,000 cannot introduce products to the marketplace that are not compliant with the new rule.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
